Natera (NTRA) Projected to Post Quarterly Earnings on Wednesday

Natera (NASDAQ:NTRA) is projected to post its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Natera to post earnings of ($0.42) per share and revenue of $447.91 million for the quarter.

Natera Price Performance

Shares of NTRA stock opened at $169.38 on Wednesday. The stock’s fifty day moving average is $167.86 and its 200-day moving average is $143.93. The stock has a market capitalization of $22.36 billion, a PE ratio of -96.24 and a beta of 1.66. Natera has a 52 week low of $68.03 and a 52 week high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Insider Transactions at Natera

In related news, insider John Fesko sold 663 shares of Natera stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the sale, the insider now owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 78,553 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the transaction, the chief executive officer now directly owns 267,629 shares in the company, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 295,772 shares of company stock valued at $49,741,699 over the last 90 days. 7.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on NTRA shares. Sanford C. Bernstein raised their price target on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, January 10th. JPMorgan Chase & Co. raised their price target on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Craig Hallum raised their price target on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Morgan Stanley raised their target price on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Finally, Guggenheim raised their target price on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $165.88.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.